GSK’s ratings under pressure with Novartis buy
UK drug maker GlaxoSmithKline has agreed to buy Novartis’s 36.5% stake in the pair’s consumer healthcare joint venture, just days after backing out of an acquisition for a similar Pfizer unit.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts